Ampersand Capital Partners Majority Recapitalizes Phosphorex

Ampersand Capital Partners Majority Recapitalizes New England Peptide

October 7, 2019

Biotechnology

Ampersand Capital Partners completed a majority recapitalization of New England Peptide to support the company's worldwide growth initiatives and expand its peptide synthesis capabilities. As part of the transaction, Dr. José de Chastonay was appointed Executive Chairman; founders Sam and Jennifer Massoni remain noted in the announcement.

NOF Corporation Makes Strategic Minority Investment in Phosphorex

August 9, 2024

Pharmaceuticals

Japanese chemical manufacturer NOF Corporation completed a strategic minority investment in Phosphorex, a Hopkinton, Massachusetts-based drug-delivery CDMO backed by Ampersand Capital Partners. The investment will fund acceleration of Phosphorex's cGMP capabilities and strengthen collaboration on lipid nanoparticle (LNP) technologies and NOF's COATSOME SS series ionizable lipids.

Ampersand Capital Partners Majority Recapitalizes N2 Biomedical

June 18, 2019

Medical Devices

Ampersand Capital Partners completed a majority recapitalization of N2 Biomedical, a Bedford, Massachusetts-based provider of coating and surface treatment solutions for the medical device industry. The transaction positions N2 to accelerate growth and broaden its service offering; Ampersand also supported the appointment of Randall Sword as President and CEO while co-founders remain shareholders.

Ampersand Capital Partners Invests in Genezen Laboratories

January 5, 2021

Biotechnology

Ampersand Capital Partners has made a majority growth-equity investment in Genezen Laboratories, a cell and gene therapy CDMO, to fund completion of a 25,000 sq. ft. cGMP lentiviral vector production facility and expand process development and analytical testing capabilities. The capital will support Genezen's capability expansion across upstream/downstream processing, analytical testing, and cGMP vector production to serve early‑phase and growth-stage cell and gene therapy developers.

Ampersand Capital Partners Acquires Peptides International and Merges It with New England Peptide

December 16, 2019

Biotechnology

Ampersand Capital Partners has acquired Peptides International and merged it into its existing portfolio company, New England Peptide, creating a combined provider of custom and catalog peptide synthesis services. The transaction is an add-on to Ampersand’s New England Peptide platform to expand scale, capabilities, and customer relationships across pharmaceutical, biotech and academic markets.

Ampersand Capital Partners Invests in Alliance Pharma

November 18, 2021

Healthcare Services

Ampersand Capital Partners has made a growth equity investment in Alliance Pharma, a Malvern, Pennsylvania–based bioanalytical CRO. The funding will support Alliance’s expansion of global reach, scientific capabilities, and operational capacity while founder Frank Li remains a significant shareholder.